MedTrace Logo

XELOX Versus FOLFOX for Advanced Gastric Cancer (AGC)

NCT01748851 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2014-11-04

No results posted yet for this study

Summary

The purpose of this study is to identify the non-inferiority of the combination therapy of Capecitabine and Oxaliplatin compared with the combination therapy of Fluorouracil/Folinic acid and Oxaliplatin in patients with advanced gastric cancer.

Conditions

  • Gastric Carcinoma Stage IV

Interventions

DRUG

XELOX

capecitabine 1000mg/m2 bid po D1-D14

DRUG

FOLFOX

5-FU 400mg/m2 iv push D1, 5-FU 1200mg/m2 over 22hr D1,D2

Sponsors & Collaborators

  • Dong-A University Hospital

    lead OTHER

Principal Investigators

  • Sung Yong Oh, M.D. · Dong-A University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2014-09-30
Completion
2014-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01748851 on ClinicalTrials.gov